Methodological Gaps in Economic Evaluations of ...

By João L. Carapinha

March 10, 2026

Economic evaluations of vaccines targeting multi-disease combinations, such as hepatitis A/B or measles-mumps-rubella (MMR), reveal critical methodological shortcomings in this
Enhertu Early Breast Cancer: FDA Priority Review for Reducing Recurrence Risk
Rapid Genetic Testing Mitigates Gentamicin-Induced Hearing Loss in Neonates
EMA’s Clinical Trials Guidance for Enhancing Flexibility During Public ...
Portugal Clinical Trials Regulation: A Comprehensive Framework for EU Complia...
Aspen Pharmacare Financial Growth: Navigating H1 2026’s Transitional Fi...
South Africa’s Push for Local Lenacapavir Production to Enhance HIV Pre...
Urgent Call for Enhanced Precision Oncology Access in Europe
Harmonizing Non-Clinical Evaluation of Microbiome Medicinal Products in the EU
Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Manage...
CHMP February 2026 Approvals: New Breakthroughs in Medicines and Biosimilars
EMA’s mCombriax Vaccine Recommendation
HERNEXEOS Lung Cancer Treatment: First FDA Approval for HER2-Mutant NSCLC